Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign in or Register to read more
7488
Related Questions
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How do you differentiate demoralization from depression during cancer treatment?
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
How would you manage elevated vWF and FVIII levels in a patient with a family history of coagulopathy?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
How do you treat factor XI deficient patients with surgery or trauma related bleeding?